Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Free Cash Flow for 18 consecutive years, with -$208.0 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow rose 10.34% year-over-year to -$208.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 53.2% YoY) and the FY2025 annual result came in at $1.1 billion, up 53.27% from the prior year.
• Free Cash Flow retreated to -$208.0 million in Q1 2026 per TEVA's latest filing, from $1.0 billion in the prior quarter.
• Over the last five years, Free Cash Flow for TEVA reached as high as $1.1 billion in Q4 2023 and fell as low as -$284.0 million in Q1 2023.
• A 5-year average of $210.2 million and a median of $131.0 million in 2025 frame the typical range for Free Cash Flow.
• The largest YoY upside for Free Cash Flow was 5225.0% in 2023 against a maximum downside of 134.2% in 2023.
• Year by year, Free Cash Flow stood at $831.0 million in 2022, then climbed by 28.16% to $1.1 billion in 2023, then sank by 58.12% to $446.0 million in 2024, then soared by 127.8% to $1.0 billion in 2025, then tumbled by 120.47% to -$208.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$208.0 million, $1.0 billion, and $233.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.